Laia Reverte-Salisa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laia Reverte-Salisa has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Irina Iriady
Life and Medical Science Institute, University of Bonn, Bonn, Germany
2 shared publications- Irmgard Förster
Immunology and Environment, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany
2 shared publications Alexander Pfeifer
Institute of Pharmacology and Toxicology, University Hospital Bonn, University of Bonn
1 shared publication- Alexander Pfeifer
Institute of Pharmacology and Toxicology, University Hospital, University of Bonn, 53127 Bonn, Germany
1 shared publication - Birte Niemann
Institute of Pharmacology and Toxicology, University Hospital, University of Bonn, Bonn, Germany
1 shared publication - Charlotte Esser
IUF – Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany
1 shared publication
Latest Publications
- Open Access
Mathematical Modeling of the Canonical Aryl Hydrocarbon Receptor Pathway in murine bone-marrow-derived macrophages
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor involved in xenobiotic sensing, as well as development, immunity, and tissue homeostasis. AhR signaling proceeds through a canonical and a non-canonical branch. It remains unclear which biochemical steps of the canonical pathway are responsible for distinct ligand specific transcriptional responses. Here, we developed a mechanistic ordinary differential equation model of the canonical AhR pathway in murine bone-marrow-derived macrophages. We calibrated it to time-resolved qPCR measurements of Cyp1a1 and Ahrr mRNA in mouse bone-marrow-derived macrophages exposed to three structurally diverse, environmentally relevant ligands with known immunomodulatory activity: 3-methylcholanthrene, indolo[3,2-b]carbazole and bisphenol A. Calibration used global optimization under a heteroskedastic likelihood. To dissect ligand specificity, we evaluated 528 distinct candidate models that allow one or two ligand-involving reaction rate constants to vary. Model selection revealed a dominant regime governed by faster promoter binding. Furthermore, it supported that ICZ requires no ligand-specific parameter relative to 3MC and most differences are visible in the expression levels of Ahrr mRNA. In addition, the model revealed that differences at the promoter binding and transcriptional levels were better supported than upstream signaling events. The resulting model is made available in SBML and PEtab formats for reproducibility, and to enable further research into whether ligand-specific effects are conserved or rewired across cell types.
Open AccessMathematical Modeling of the Canonical Aryl Hydrocarbon Receptor Pathway in murine bone-marrow-derived macrophages
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor involved in xenobiotic sensing, as well as development, immunity, and tissue homeostasis. AhR signaling proceeds through a canonical and a non-canonical branch. It remains unclear which biochemical steps of the canonical pathway are responsible for distinct ligand specific transcriptional responses. Here, we developed a mechanistic ordinary differential equation model of the canonical AhR pathway in murine bone-marrow-derived macrophages. We calibrated it to time-resolved qPCR measurements of Cyp1a1 and Ahrr mRNA in mouse bone-marrow-derived macrophages exposed to three structurally diverse, environmentally relevant ligands with known immunomodulatory activity: 3-methylcholanthrene, indolo[3,2-b]carbazole and bisphenol A. Calibration used global optimization under a heteroskedastic likelihood. To dissect ligand specificity, we evaluated 528 distinct candidate models that allow one or two ligand-involving reaction rate constants to vary. Model selection revealed a dominant regime governed by faster promoter binding. Furthermore, it supported that ICZ requires no ligand-specific parameter relative to 3MC and most differences are visible in the expression levels of Ahrr mRNA. In addition, the model revealed that differences at the promoter binding and transcriptional levels were better supported than upstream signaling events. The resulting model is made available in SBML and PEtab formats for reproducibility, and to enable further research into whether ligand-specific effects are conserved or rewired across cell types.
- Open Access
Differential cell type-specific function of the aryl hydrocarbon receptor and its repressor in diet-induced obesity and fibrosis
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor regulating xenobiotic responses as well as physiological metabolism. Dietary AhR ligands activate the AhR signaling axis in the intestine and throughout the organism, whereas AhR activation is negatively regulated by the AhR repressor (AhRR). While AhR-deficient mice are known to be resistant to diet-induced obesity (DIO), we here demonstrate that AhRR deficiency also leads to a robust, but not as profound protection from DIO and hepatosteatosis. Under conditions of DIO, AhRR -/- mice did not accumulate TCA cycle intermediates in the circulation in contrast to wild-type (WT) mice, indicating protection from metabolic dysfunction. This effect could be mimicked by dietary supplementation of AhR ligands in WT mice. Because of the predominant expression of the AhRR in myeloid cells, AhRR-deficient macrophages were analyzed for changes in metabolism and showed major metabolic alterations regarding oxidative phosphorylation and mitochondrial activity as well as increased expression of genes involved in de novo lipogenesis and mitochondrial biogenesis. Mice with a genetic deficiency of the AhRR in myeloid cells did not show alterations in weight gain after high fat diet (HFD) but demonstrated ameliorated liver damage compared to control mice. Further, deficiency of the AhR in myeloid cells also did not affect weight gain but led to enhanced liver damage and adipose tissue fibrosis compared to controls. Although conditional ablation of either the AhR or AhRR in myeloid cells did not recapitulate the phenotype of the global knockout, our findings suggest that enhanced AhR signaling in myeloid cells deficient for AhRR protects from diet-induced liver damage and fibrosis, whereas myeloid cell-specific AhR deficiency is detrimental.
Open AccessDifferential cell type-specific function of the aryl hydrocarbon receptor and its repressor in diet-induced obesity and fibrosis
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor regulating xenobiotic responses as well as physiological metabolism. Dietary AhR ligands activate the AhR signaling axis in the intestine and throughout the organism, whereas AhR activation is negatively regulated by the AhR repressor (AhRR). While AhR-deficient mice are known to be resistant to diet-induced obesity (DIO), we here demonstrate that AhRR deficiency also leads to a robust, but not as profound protection from DIO and hepatosteatosis. Under conditions of DIO, AhRR -/- mice did not accumulate TCA cycle intermediates in the circulation in contrast to wild-type (WT) mice, indicating protection from metabolic dysfunction. This effect could be mimicked by dietary supplementation of AhR ligands in WT mice. Because of the predominant expression of the AhRR in myeloid cells, AhRR-deficient macrophages were analyzed for changes in metabolism and showed major metabolic alterations regarding oxidative phosphorylation and mitochondrial activity as well as increased expression of genes involved in de novo lipogenesis and mitochondrial biogenesis. Mice with a genetic deficiency of the AhRR in myeloid cells did not show alterations in weight gain after high fat diet (HFD) but demonstrated ameliorated liver damage compared to control mice. Further, deficiency of the AhR in myeloid cells also did not affect weight gain but led to enhanced liver damage and adipose tissue fibrosis compared to controls. Although conditional ablation of either the AhR or AhRR in myeloid cells did not recapitulate the phenotype of the global knockout, our findings suggest that enhanced AhR signaling in myeloid cells deficient for AhRR protects from diet-induced liver damage and fibrosis, whereas myeloid cell-specific AhR deficiency is detrimental.
- Open Access
- 9 January 2024
- Published by Springer Nature in Nature Cell Biology
- Vol. 26 (1) , 113-123
EPAC1 enhances brown fat growth and beige adipogenesis
Brown adipose tissue (BAT) is a central thermogenic organ that enhances energy expenditure and cardiometabolic health. However, regulators that specifically increase the number of thermogenic adipocytes are still an unmet need. Here, we show that the cAMP-binding protein EPAC1 is a central regulator of adaptive BAT growth. In vivo, selective pharmacological activation of EPAC1 increases BAT mass and browning of white fat, leading to higher energy expenditure and reduced diet-induced obesity. Mechanistically, EPAC1 coordinates a network of regulators for proliferation specifically in thermogenic adipocytes, but not in white adipocytes. We pinpoint the effects of EPAC1 to PDGFRα-positive preadipocytes, and the loss of EPAC1 in these cells impedes BAT growth and worsens diet-induced obesity. Importantly, EPAC1 activation enhances the proliferation and differentiation of human brown adipocytes and human brown fat organoids. Notably, a coding variant ofRAPGEF3(encoding EPAC1) that is positively correlated with body mass index abolishes noradrenaline-induced proliferation of brown adipocytes. Thus, EPAC1 might be an attractive target to enhance thermogenic adipocyte number and energy expenditure to combat metabolic diseases.
- 9 January 2024
- Published by Springer Nature in Nature Cell Biology
- Vol. 26 (1) , 113-123
Open AccessEPAC1 enhances brown fat growth and beige adipogenesis
Brown adipose tissue (BAT) is a central thermogenic organ that enhances energy expenditure and cardiometabolic health. However, regulators that specifically increase the number of thermogenic adipocytes are still an unmet need. Here, we show that the cAMP-binding protein EPAC1 is a central regulator of adaptive BAT growth. In vivo, selective pharmacological activation of EPAC1 increases BAT mass and browning of white fat, leading to higher energy expenditure and reduced diet-induced obesity. Mechanistically, EPAC1 coordinates a network of regulators for proliferation specifically in thermogenic adipocytes, but not in white adipocytes. We pinpoint the effects of EPAC1 to PDGFRα-positive preadipocytes, and the loss of EPAC1 in these cells impedes BAT growth and worsens diet-induced obesity. Importantly, EPAC1 activation enhances the proliferation and differentiation of human brown adipocytes and human brown fat organoids. Notably, a coding variant ofRAPGEF3(encoding EPAC1) that is positively correlated with body mass index abolishes noradrenaline-induced proliferation of brown adipocytes. Thus, EPAC1 might be an attractive target to enhance thermogenic adipocyte number and energy expenditure to combat metabolic diseases.